Latest

10.29.2020

COVID-19 viral biotech Atea Pharmaceuticals prices upsized IPO at $24 high end

Read Article
10.22.2020

Roche to pay Atea $350M for ex-U.S. rights to COVID-19 antiviral

Read Article
08.18.2020

FDA greenlights expansion of COVID-19 study to VCU Medical Center after positive data

Read Article
07.16.2020

CalciMedica's Auxora Shows Promise As COVID-19 Treatment, Patients Recovered Twice As Fast

Read Article
Up NextAbout Us